Oyster Point Pharma — Investor Presentation (June 2020)
53 slides from Oyster Point Pharma's investor presentation, Jun 9, 2020
Slide 1: Corporate Presentation June 2020
Corporate Presentation June 2020 NASDAQ: OYST
Slide 2: Disclaimers and Forward-looking Statements
Disclaimers and Forward-looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current beliefs, expectations and assumptions of Oyster Point Pharma, Inc. (the “Company,” “we” or “our”) reg
Slide 3: ©2020 Oyster Point Pharma, Inc.: Confidential & Proprietary I 3
©2020 Oyster Point Pharma, Inc.: Confidential & Proprietary I 3
Slide 4: OC-01 Nasal Spray for Dry Eye Disease
OC-01 Nasal Spray for Dry Eye Disease Preservative-free nasal spray with 50 uL spray delivered twice daily to each nostril Novel mechanism of action to restore tear film homeostasis with natural tear production Rapid onset of action demonstrated in clinical trials to significantly improve signs and
Slide 5: Significant Unmet Need in the Treatment of Dry Eye Disease
Significant Unmet Need in the Treatment of Dry Eye Disease Dry Eye Affects Limitations of current treatments ~34 MILLION ADULTS of all ages in the U.S. alone1 • Mechanisms of action only and >340 million worldwide2 address inflammation ~16 MILLION ADULTS • Slow onset of action, measured in weeks to
Slide 6: There is No Substitute for Natural Tear Film
There is No Substitute for Natural Tear Film A healthy tear film lubricates and protects the eyes from injury and infection, washes away foreign particles, and contributes refractive power for clear vision Growth factors, such as nerve growth factor (NGF) and epidermal growth factor (EGF), found in
Slide 7: Loss of Tear Film Leads to Cycle of Progression of Dry Eye Disease
Loss of Tear Film Leads to Cycle of Progression of Dry Eye Disease. OC-01 Targets Re-Establishing Tear Film Production Healthy Ocular Surface Loss of Tear Film Homeostasis Cycle of Dry Eye Disease Leads to Inflammation Tear Film Homeostasis Fundamental Characteristic of DED and Cell Damage Tear Defi
Slide 8: OC-01 Breaks the Cycle of Dry Eye Disease Progression
OC-01 Breaks the Cycle Progression of Dry Eye Disease by Re- Establishing Natural Tear Film Production Through a Novel MOA Healthy Ocular Surface Loss of Tear Film Homeostasis Cycle of Dry Eye Disease Leads to Inflammation Tear Film Homeostasis Fundamental Characteristic of DED and Cell Damage Tear
Slide 9: OC-01's Nasal Delivery is Critical to the Novel MOA
OC-01’s Nasal Delivery is Critical to the Novel MOA Parasympathetic Nervous System controls tear film homeostasis The trigeminal nerve is accessible within the nasal cavity, activated by OC-01 by stimulating nicotinic acetylcholine receptors (nAChR) The trigeminal nerve provides the pathway for para
Slide 10: Tear Film is Produced by the Lacrimal Functional Unit
Tear Film is Produced by the Lacrimal Functional Unit LACRIMAL GLANDS Produce the aqueous which contains proteins, enzymes, antibodies and growth factors that are cytoprotective, anti- inflammatory, and anti-microbial. MEIBOMIAN GLANDS Produce the lipid layer which reduces evaporation and promotes t
Slide 11: OC-01 is a Selective Nicotinic Agonist
OC-01 is a Selective Nicotinic Agonist • Preservative-free nasal spray containing the selective nicotinic acetylcholine receptor agonist, varenicline. • Binds to receptors located on the trigeminal nerve readily accessible within anterior portion of the nasal cavity to open ion channels and depolari
Slide 12: OC-01 Nasal Spray Clinical Development Program
OC-01 Nasal Spray Clinical Development Program 1 Phase 1 Phase 2b Phase 3 Phase 2 28-Day 28-Day Long-term 84-Day PK Study Safety & Efficacy Safety & Efficacy Safety & Efficacy Complete Complete Complete Complete ©2020 Oyster Point Pharma, Inc.: Confidential & Proprietary I 12
Slide 13: ZEN Phase 2 Study Design
ZEN Phase 1 Study Design Open-Label, Single-Center, Randomized, 2-way Crossover Study to Evaluate the Relative Bioavailability of Varenicline Administered as OC-01 Nasal Spray Compared to Varenicline Administered Orally n=11 1.2 mg/ml Varenicline OC-01 Oral Tablet Nasal Spray 1mg Randomized 14 Day W
Slide 14: OC-01 Nasal Spray Provides Low Systemic Exposure
OC-01 Nasal Spray Provides Low Systemic Exposure Highlights: Systemic Exposure • Relative bioavailability* of OC- Mean Plasma Concentration vs. Time 01 nasal spray was 13 times lower as compared to oral varenicline • Maximal concentration** of OC- 01 nasal spray was 14 times lower as compared to ora
Slide 15: OC-01 Nasal Spray Clinical Development Program
OC-01 Nasal Spray Clinical Development Program 1 Phase 1 Phase 2b Phase 3 Phase 2 28-Day 28-Day Long-term 84-Day PK Study Safety & Efficacy Safety & Efficacy Safety & Efficacy Complete Complete Complete Complete ©2020 Oyster Point Pharma, Inc.: Confidential & Proprietary I 15
Slide 16: ONSET-1 Phase 2b Study Design
ONSET-1 Phase 2b Study Design Multicenter, Randomized, Double-Masked, Vehicle-Controlled Clinical Trial to Evaluate the Safety and Efficacy of OC-01 Nasal Spray on the Signs and Symptoms of Dry Eye Disease 1.2 mg/ml n=44 OC-01 Nasal Spray Primary (Sign) Endpoint: • Schirmer’s Score at Week 4 (Day 28
Slide 17: Demographics and Baseline Characteristics
Demographics[1] and Baseline Characteristics[2] OC-01 OC-01 OC-01 Control Total 0.12 mg / mL 0.6 mg / mL 1.2 mg / mL (n=43) (n=182) (n=47) (n=48) (n=44) Mean Age at Randomization (years) 64.0 (10.3) 64.2 (12.7) 66.5 (9.4) 67.4 (10.6) 65.5 (10.8) Age Range (min, max) 32, 89 24, 89 49, 88 22, 84 22, 8
Slide 18: Statistically Significant Improvement in Signs
Statistically Significant Improvement in Signs Mean Change from Baseline in Schirmer’s % Subjects with ≥ 10mm Change from Baseline Score (mm) – Week 4 in Schirmer’s Score – Week 4 Primary (Sign) Endpoint Exploratory (Sign) Endpoint[1] P<0.001 P<0.001 P=0.001* P<0.001* P=0.001* 11.4 11.1 10.1 54% 48%
Slide 19: Statistically Significant Improvement in Symptoms
Statistically Significant Improvement in Symptoms Mean Change from Baseline in Eye Dryness Mean Change from Baseline in Eye Dryness Score (mm) in CAE – Week 31 Score (mm) in Clinic – Week 42 Secondary (Symptom) Endpoint Secondary (Symptom) Endpoint n=42 n=44 n=45 n=38 n=43 n=47 n=46 n=40 -4.4 -5.6 -
Slide 20: Safety and Tolerability Profile
Safety and Tolerability Profile Adverse Events Potentially Related to OC-01 Administration Events in >5% of Subjects OC-01 OC-01 OC-01 0.12 mg / mL 0.6 mg / mL 1.2 mg / mL Control (n=47) (n=48) (n=44) Sneeze after any installation 29 (62) 38 (79) 37 (84) 0 Cough after any instillation 4 (9) 6 (13) 1
Slide 21: OC-01 Nasal Spray Clinical Development Program
OC-01 Nasal Spray Clinical Development Program 1 Phase 1 Phase 2b Phase 3 Phase 2 28-Day 28-Day Long-term 84-Day PK Study Safety & Efficacy Safety & Efficacy Safety & Efficacy Complete Complete Complete Complete ©2020 Oyster Point Pharma, Inc.: Confidential & Proprietary I 21
Slide 22: ONSET-2 Phase 3 Study Design
ONSET-2 Phase 3 Study Design Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy and Safety of OC-01 Nasal Spray on the Signs and Symptoms of Dry Eye Disease 1.2 mg/ml Primary (Sign) Endpoint: n=246 OC-01 • Categorical Schirmer’s Score at Week 4 (Day 28) Nasal
Slide 23: ONSET-2 Phase 3 Study Design
ONSET-2 Phase 3 Study Design Important Study Design Elements: • No placebo run-in period utilized as part of the study design, same as ONSET-1, designed to reflect real world experience • Broad dry eye subject eligibility criteria • Subjects could enter with an Eye Dryness Score from 0 – 100 • Main
Slide 24: Demographics and Baseline Characteristics
Demographics[1] and Baseline Characteristics[2] OC-01 OC-01 Control Total 0.6 mg / mL 1.2 mg / mL (n=252) (n=758) (n=260) (n=246) Mean Age at Randomization (years) 58.4 59.6 58.4 58.8 Age Range (min, max) 23, 95 22, 91 22, 91 22, 95 Sex Male 51 (20.2) 66 (25.4) 65 (26.4) 182 (24.0) Female 201 (79.8)
Slide 25: Statistically Significant Improvement in Signs
Statistically Significant Improvement in Signs % Subjects with ≥ 10 mm Change from Baseline in Schirmer’s Score (mm) - Week 4 - LOCF Primary (Sign) Endpoint p<0.0001 p<0.0001 49% 47% 28% % Subjects % n=252 n=260 n=246 Control 0.6 mg/ml 1.2 mg/ml ITT-population Cochran-Mantel-Haenszel (CMH) test cont
Slide 26: Statistically Significant Improvement in Signs
Statistically Significant Improvement in Signs % Subjects with ≥ 10 mm Change from Baseline in Schirmer’s Score (mm) - Week 4 Primary (Sign) Endpoint p<0.0001 p<0.0001 47% 44% 26% % Subjects % n=220 n=227 n=216 Control 0.6 mg/ml 1.2 mg/ml ITT-population (excluding sites 48 and 51) Cochran-Mantel-Hae
Slide 27: Study Comparison - Statistically Significant Improvement in Signs
Study Comparison - Statistically Significant Improvement in Signs % Subjects with ≥ 10 mm Change from Baseline in Schirmer’s Score (mm) - Week 4 p<0.001* p=0.001* p<0.0001 p<0.0001 60% 60% 54% 50% 48% 50% 47% 44% 40% 40% 30% 30% 26% % Subjects % % Subjects % 20% 20% 14% 10% 10% 0% 0% n=43 n=46 n=40
Slide 28: Statistically Significant Improvement in Signs
Statistically Significant Improvement in Signs Mean Change from Baseline in Schirmer’s Score (mm) - Week 4 - LOCF Secondary (Sign) Endpoint p<0.0001* p<0.0001* 11.3 11.5 6.3 Schirmer’s Score (mm) Score Schirmer’s n=248 n=251 n=235 Control 0.6 mg/ml 1.2 mg/ml ITT-population, Least Square (LS) means w
Slide 29: Statistically Significant Improvement in Signs
Statistically Significant Improvement in Signs Mean Change from Baseline in Schirmer’s Score (mm) - Week 4 Secondary (Sign) Endpoint p<0.0001* p<0.0001* 11.0 11.2 5.9 Mean Change inChange Schirmer’sMean Score (mm) n=213 n=218 n=205 Control 0.6 mg/ml 1.2 mg/ml ITT-population (excluding sites 48 and 5
Slide 30: Study Comparison - Statistically Significant Improvement in Signs
Study Comparison - Statistically Significant Improvement in Signs Mean Change from Baseline in Schirmer’s Score (mm) - Week 4 p<0.001 p<0.001 p<0.0001* p<0.0001* 12 11.4 12 11.1 11.0 11.2 10 10 8 8 5.9 6 6 3.7 4 4 2 2 Mean Mean Change Score in Schirmer’s (mm) Mean Mean Change Score in Schirmer’s (mm
Slide 31: Statistically Significant Improvement in Symptoms
Statistically Significant Improvement in Symptoms Mean Change in Baseline Eye Dryness Score – Week 1, 2 & 4 - LOCF Secondary (Symptom) Endpoints Week 1 Week 2 Week 4 n=248 n=254 n=239 n=248 n=255 n=239 n=248 n=255 n=242 -13.3 -12.7 -15.7 -15.4 -15.4 -16.5 EDS EDS Score (mm) -17.9 p<0.05* p=0.008* -1
Slide 32: Study Comparison - Statistically Significant Improvement in Symptoms
Study Comparison - Statistically Significant Improvement in Symptoms Mean Change in Baseline Eye Dryness Score - Week 4 N=43 N=46 N=40 N=241 N=248 N=233 0 0 -5 -5 -5.6 -10 -10 -15 -15 -15.4 -15.4 p=0.13 -20 -19.0 -20 Mean Change in EDS Score (mm) Score EDS in Change Mean Mean Change in EDS Score (mm
Slide 33: Statistically Significant Improvement in Symptoms
Statistically Significant Improvement in Symptoms Mean Change in Baseline Eye Dryness Score Secondary (Symptom) Endpoints Week 1 Week 2 Week 4 n=248 n=254 n=239 n=248 n=251 n=232 n=241 n=248 n=233 -13.3 -12.8 -15.7 -15.4 -15.8 -16.5 -17.9 p<0.05* p=0.009* -19.7 P<0.001 Mean Change in Change EDS Mean
Slide 34: Demographics and Baseline Characteristics
Demographics[1] and Baseline Characteristics[2] OC-01 OC-01 Baseline Eye Dryness Score > 40 Control Total 0.6 mg / mL 1.2 mg / mL (n=191) (n=583) (n=200) (n=192) Mean Age at Randomization (years) 58.0 58.9 58.0 58.3 Age Range (min, max) 23, 86 22, 85 22, 91 22, 91 Sex Male 36 (18.8) 48 (24.0) 49 (25
Slide 35: Statistically Significant Improvement in Signs
Statistically Significant Improvement in Signs % Subjects with ≥ 10 mm Change from Baseline in Schirmer’s Score (mm) - Week 4 Baseline Eye Dryness Score > 40 EDS-LOCF P=0.0001 P=0.0002 47% 48% 27% % Subjects % n=191 n=200 n=192 Control 0.6 mg/ml 1.2 mg/ml ITT-population Cochran-Mantel-Haenszel (CMH)
Slide 36: Statistically Significant Improvement in Symptoms
Statistically Significant Improvement in Symptoms Mean Change in Baseline Eye Dryness Score – Week 1, 2 & 4 Baseline Eye Dryness Score > 40 EDS - LOCF Secondary (Symptom) Endpoints Week 1 Week 2 Week 4 n=187 n=196 n=186 n=187 n=196 n=186 n=187 n=196 n=189 -15.9 -17.0 -20.3 -20.8 -21.6 -20.9 EDS EDS
Slide 37: Improvement in Symptoms in CAE
Improvement in Symptoms in CAE Mean Change in Eye Dryness Score (5 min post administration) from Baseline in Controlled Adverse Environment (CAE) – Week 4 Secondary (Symptom) Endpoint n=169 n=187 n=171 -7.4 -9.0 -10.3 p=0.50 Mean Change in Change EDS Mean Score (mm) P<0.001p=0.20 P=0.001 Control 0.6
Slide 38: Improvement in Symptoms Pre-CAE
Improvement in Symptoms Pre-CAE Mean Change in Eye Dryness Score from Baseline Pre-CAE n=212 n=215 n=197 -14.7 -16.9 p=0.31 -19.3 p=0.04 Mean Change in Change EDS Mean Score (mm) P<0.001 P=0.001 Control 0.6 mg/ml 1.2 mg/ml ITT-population (excluding sites 45 and 48), Least Square (LS) means were deri
Slide 39: OC-01 Shows Benefit in CAE vs. Control
OC-01 Shows Benefit in CAE vs. Control Mean Eye Dryness Score in CAE (Controlled Adverse Environment) 60 Mean EDS at 2 Hours Control Post-Hoc Analysis Control 59 55 0.6 mg/ml 0.6 mg/ml 56 1.2 mg/ml 52 1.2 mg/ml 50 45 40 Mean EDS at Time 0 Mean EDS Score (mm) Control 35 35 0.6 mg/ml 35 1.2 mg/ml 37 3
Slide 40: Improvement in Symptoms in CAE
Improvement in Symptoms in CAE Mean Change in Eye Dryness Score After 2 hours in CAE vs. Baseline Post-Hoc Analysis n=209 n=195 -13.7 -20.7 Mean Change in Change EDS Mean Score (mm) P<0.001 P=0.001 p=0.008 [1] Control 1.2 mg/ml [1] Post-Hoc Analysis ITT-population (excluding sites 45 and 48), Least
Slide 41: Improvement in Symptoms in CAE
Improvement in Symptoms in CAE Area Under the Curve in CAE (Eye Dryness Score) Post-Hoc Analysis 1072.2 p=0.01[1] 597.2 Mean Change in Change EDS Mean Score (mm) P<0.001 n=209 n=196 Control 1.2 mg/ml [1] Post-Hoc Analysis ITT-population (excluding sites 45 and 48), Least Square (LS) means were deriv
Slide 42: Summary of Treatment-Emergent Adverse Events
Summary of Treatment - Emergent Adverse Events Control 0.6 mg/mL 1.2 mg/mL Total (n=251) (n=260) (n=245) (n=756) n (%) n (%) n (%) n (%) Subjects with any Treatment Emergent Adverse Events (TEAE) 135 (53.8) 252 (96.9) 241 (98.4) 628 (83.1) Subjects with any Treatment-Related Treatment Emergent Serio
Slide 43: Adverse Event Profile
Adverse Event Profile Treatment-Emergent Adverse Events in >5% of Subjects Potentially Related to OC-01 OC-01 OC-01 Control Total 0.6 mg / mL 1.2 mg / mL (n=251) (n=756) (n=260) (n=245) Sneeze after any installation 73 (29.1) 247 (95.0) 237 (96.7) 557 (73.7) Cough after any instillation 5 (2.0) 49 (
Slide 44: OC-01 Nasal Spray Clinical Development Program
OC-01 Nasal Spray Clinical Development Program 1 Phase 1 Phase 2b Phase 3 Phase 2 28-Day 28-Day Long-term 84-Day PK Study Safety & Efficacy Safety & Efficacy Safety & Efficacy Complete Complete Complete Complete ©2020 Oyster Point Pharma, Inc.: Confidential & Proprietary I 44
Slide 45: MYSTIC Phase 3 Study Design
MYSTIC Phase 2 Study Design Single Center, Randomized, Controlled, Single-masked Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease Primary Endpoint: n=41 1.2 mg/ml OC-01 • Mean Change in Schirmer’s Score at Day 84 Nasal Spray Randomized n=41 0.6 mg/ml 1
Slide 46: Statistically Significant Improvement in Primary Endpoint of Schirmer's Score at Day 84
Statistically Significant Improvement in Primary Endpoint of Schirmer’s Score at Day 84 Mean Change from Baseline in Schirmer’s Score (mm) LOCF Analysis Observed Analysis p=0.01 p=0.01 p<0.05 p<0.05 12.0 12.0 10.8 11.0 10.6 11.0 10.0 10.0 8.0 8.0 6.0 6.2 6.0 6.0 4.0 4.0 2.0 2.0 0.0 0.0 Day 84 Day 84
Slide 47: Showed Early & Sustained Improvement in Schirmer's Score to Day 84
Showed Early & Sustained Improvement in Schirmer’s Score to Day 84 Highlights: Mean Change from Baseline in Schirmer’s Score (mm) 13.0 12.3 • Early improvement in 11.5 mean change in 11.0 11.0 10.5 10.7 10.6 Schirmer’s score for 10.4 10.3 both dose groups 9.0 6.9 7.0 • Consistent tear film 7.0 6.3 6
Slide 48: OC-01 Nasal Spray Profile
OC-01 Nasal Spray Profile Preservative-free nasal spray with 50 uL spray delivered twice daily to each nostril Novel mechanism of action to restore tear film homeostasis with natural tear production Rapid onset of action demonstrated in clinical trials to significantly improve signs and symptoms Imp
Slide 49: Commercialization of OC-01 Nasal Spray
Commercialization of OC-01 Nasal Spray Planning 1st launch in the U.S. in Q4 2021; key commercialization strategies include: Specialty sales force Extensive education and Enable patient access to marketing campaigns OC-01 Competitively sized specialty Broad ECP education and Strategic contracting fo
Slide 50: Financial Highlights
Financial Highlights Income Statement (3/31/20): Balance Sheet (3/31/20): Initial Public Offering (11/2019): First Follow-on Offering (5/2020): $92M gross proceeds $121M gross proceeds 5.75M shares @ $16 per share 4.31M shares @ $28 per share ©2020 Oyster Point Pharma, Inc.: Confidential & Proprieta
Slide 51: Strong Global I.P. Position
Strong Global I.P. Position OC-01 (Varenicline) Nasal Spray: . U.S. license granted for varenicline tartrate by Pfizer . Five issued U.S. patents (expire 2035) relating to methods and/or formulations • Patents relating to methods of treating dry eye disease, increasing tear production, and improving
Slide 52: OC-01 Nasal Spray Expected Timeline to Approval
OC-01 Nasal Spray Expected Timeline to Approval Enrollment Complete - Q3 2018 Enrollment Complete - Q1 2020 Top-line Data - Q4 2018 Top-line Data - Q2 2020 NDA Submission - 2H 2020 NDA Approval - 2H 2021 ©2020 Oyster Point Pharma, Inc.: Confidential & Proprietary I 52
Slide 53: NASDAQ: OYST
NASDAQ: OYST
Oyster Point Pharma — Investor Presentation (June 2020) on 6ix